672 related articles for article (PubMed ID: 26839021)
1. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
2. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
3. Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.
Antonarakis ES
Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
[No Abstract] [Full Text] [Related]
4. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.
Bennett LL; Ingason A
Ann Pharmacother; 2014 Apr; 48(4):530-7. PubMed ID: 24458946
[TBL] [Abstract][Full Text] [Related]
5. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.
Quintela ML; Mateos LL; Estévez SV; Calvo OF; Herranz UA; Afonso FJ; Santomé L; Aparicio LA
Cancer Treat Rev; 2015 Mar; 41(3):247-53. PubMed ID: 25638257
[TBL] [Abstract][Full Text] [Related]
6. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
7. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
Maeda H; Saito A
Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Attard G; Antonarakis ES
Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
[No Abstract] [Full Text] [Related]
9. Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.
Modena A; Ciccarese C; Fantinel E; Bimbatti D; Tortora G; Massari F
Expert Rev Anticancer Ther; 2015; 15(9):1037-48. PubMed ID: 26134919
[TBL] [Abstract][Full Text] [Related]
10. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
Molecules; 2020 May; 25(10):. PubMed ID: 32456317
[TBL] [Abstract][Full Text] [Related]
11. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
Albiges L; Loriot Y; Massard C; Fizazi K
Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
[No Abstract] [Full Text] [Related]
12. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
Graff JN; Gordon MJ; Beer TM
Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
[TBL] [Abstract][Full Text] [Related]
13. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: © NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
BJU Int; 2017 Aug; 120(2):168-184. PubMed ID: 28719114
[No Abstract] [Full Text] [Related]
14. Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer.
Sanford M
Drugs; 2013 Oct; 73(15):1723-32. PubMed ID: 24127223
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Nakazawa M; Antonarakis ES; Luo J
Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
[TBL] [Abstract][Full Text] [Related]
16. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
Boegemann M
Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
[No Abstract] [Full Text] [Related]
17. Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.
Baciarello G; Sternberg CN
Crit Rev Oncol Hematol; 2016 Oct; 106():14-24. PubMed ID: 27637350
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
19. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
[TBL] [Abstract][Full Text] [Related]
20. Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer.
Cerasuolo M; Maccarinelli F; Coltrini D; Mahmoud AM; Marolda V; Ghedini GC; Rezzola S; Giacomini A; Triggiani L; Kostrzewa M; Verde R; Paris D; Melck D; Presta M; Ligresti A; Ronca R
Cancer Res; 2020 Apr; 80(7):1564-1577. PubMed ID: 32029552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
